<DOC>
	<DOCNO>NCT01270906</DOCNO>
	<brief_summary>Phase I dose find study solid tumor .</brief_summary>
	<brief_title>Safety CHIR-258 ( TKI258 ) Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Diagnosis histologically cytologically document , advancedstage , primary metastatic solid tumor refractory standard therapy curative standard therapy exist . Evidence measurable evaluable disease . All acute toxic affect prior radiotherapy , chemotherapy , surgical procedure must resolve National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE , Version 3.0 ) Grade â‰¤1 ; surgery must occur least 28 day prior study enrollement . Age must least 18 year . Last dose antineoplastic therapy ( except hormonal therapy ) must 21 day ; subject may continue receive luteinizing hormonereleasing hormone analog therapy prostate cancer . ECOG performance status must 0 1 . Life expectancy least 3 month . Patient must meet protocolspecified laboratory value . Concurrent therapy investigational agent . Intracranial edema , intracranial metastasis , epidural disease . Pregnant breastfeeing woman . Female subject must agree use effective contraception , must surgically sterile , must postmenopausal . Male subject must agree use effective contraception surgically sterile . The definition effective contraception base judgment investigator designate associate . All atrisk female subject must netative pregnancy test ( serum urine ) within 10 day prior start study treatment . Clinically significant cardiac disease ( New York Heart Association Class III IV ) include preexist arrhythmia , congestive heart failure , cardiomyopathy , subject baseline mean QTc interval great 450 msec ( male ) 470 msec ( female ) grade 2 high compromise leave ventricular ejection fraction ( LVEF ) determine MUGA ECHO . Dementia alter mental status would prohibit informed consent . Diabetes mellitus ( insulindependent independent disease require chronic medication ) . Previous pericarditis ; clinically significant pleural effusion previous 12 month current ascites require two interventions/month . Malabsorption syndrome uncontrolled gastrointestinal toxicity ( nausea , diarrhea , vomitting ) toxicity great NCI CTCAE grade 2 . Prior acute chonic pancreatitis etiology . Prior intraor extrahepatic biliary obstruction wtihin previous 12 month history malignant obstruction require bilary stent , unless stably treat prior obstruction blockage stent . Other severe , acute , chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation studydrug administration may interfere interpretation study result , judgment investigator , make subject inappropriate study . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Cancer</keyword>
	<keyword>Tumors</keyword>
	<keyword>Administration</keyword>
	<keyword>oral</keyword>
	<keyword>CHIR258</keyword>
	<keyword>CHIR-258</keyword>
	<keyword>CHIR 258</keyword>
	<keyword>TKI258</keyword>
	<keyword>TKI-258</keyword>
	<keyword>TKI 258</keyword>
	<keyword>dose find</keyword>
</DOC>